Literature DB >> 3802702

Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.

C H Kleinbloesem, P van Brummelen, M Danhof, H Faber, J Urquhart, D D Breimer.   

Abstract

The relevance of the rate of increase in the plasma concentration of nifedipine for the drug's hemodynamic effect was investigated in healthy volunteers. Nifedipine was given intravenously according to two regimens, each designed to produce the same steady-state concentration, but attained gradually (within 5 to 7 hours) with one regimen and rapidly (within 3 minutes) with the other. The mean steady-state concentrations obtained were 31.7 +/- 5.2 (SD) ng/ml and 29.4 +/- 9.8 ng/ml, respectively (not significant). With the gradual regimen, heart rate was unchanged and diastolic blood pressure was lowered gradually by approximately 10 mm Hg. With the rapid regimen, heart rate increased immediately and remained elevated for the duration of the infusion, whereas diastolic blood pressure did not change significantly. At the end of the gradual-rise regimen, the infusion rate was increased tenfold for 10 minutes, promptly resulting in tachycardia and a paradoxical rise in diastolic blood pressure. These divergent hemodynamic responses of the gradual- and rapid-rise regimens could well be related to differences in baroreceptor activation. It is concluded that the hemodynamic response to nifedipine is influenced by the rate of increase of its concentration in plasma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802702     DOI: 10.1038/clpt.1987.5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  42 in total

Review 1.  Interchangeability and predictive performance of empirical tolerance models.

Authors:  M Gårdmark; L Brynne; M Hammarlund-Udenaes; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  1999-02       Impact factor: 6.447

Review 2.  Central sympathoinhibitory effects of calcium channel blockers.

Authors:  F H Leenen; M Ruzicka; B S Huang
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 3.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

4.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers.

Authors:  Meindert Danhof; Gunnar Alvan; Svein G Dahl; Jochen Kuhlmann; Gilles Paintaud
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

Review 6.  Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions.

Authors:  E J van Hoogdalem; A G de Boer; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

7.  The influence of drug input rate on the development of tolerance to frusemide.

Authors:  M Wakelkamp; G Alván; H Scheinin; J Gabrielsson
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

8.  Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery.

Authors:  M Borenstein; R Shupak; R Barnette; G Cooney; W Johnson; T B Tzeng
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 9.  Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm.

Authors:  D D Breimer; M Danhof
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

10.  Integrated TK-TD modeling for drug-induced concurrent tachycardia and QT changes in beagle dogs.

Authors:  Fan Wu; Tycho Heimbach; Panos Hatsis; Hai-Ming Tang; Raviprakash Dugyala; Qin Yue; Tao Wang; Handan He
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-22       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.